With dermatologic side effects being fairly prevalent following vaccination against COVID‐
19, and the multitude of studies aiming to report and analyze these adverse events, the need …

This study aims to provide comparative data on clinical features and in-hospital outcomes
among US adults admitted to the hospital with COVID-19 and influenza infection using a …

While mucocutaneous manifestations of COVID-19 have been frequently reported and
added to our knowledge every day during the pandemic, another issue is the COVID-related …

Objectives Earlier diagnosis and the best management of virus‐related, drug‐related or
mixed severe potentially life‐threatening mucocutaneous reactions of COVID‐19 patients …

Cases of filler reactions after COVID‐19 vaccination have been reported. Here, we present
the first case of delayed‐type reaction (DTR) to non‐hyaluronic acid Polycaprolactone …

This narrative review article was conducted to lay out a summarized but exhaustive review of
current literature over mucocutaneous manifestations in 4 dimensions of SARS‐CoV‐2 …

Background Rituximab is a FDA-approved monoclonal antibody for adults with moderate to
severe potentially life-threatening pemphigus vulgaris. Recent studies have focused on …

The COVID‐19 pandemic has been extra challenging for patients with chronic diseases.
Psoriasis is one of the chronic conditions that its treatment mostly relies on …

With the introduction of the influenza vaccine in the official immunization schedule of most
countries, several data regarding the efficacy, tolerability, and safety of influenza …

Background The current absence of gold‐standard or all‐aspect favorable therapies for
COVID‐19 renders a focus on multipotential drugs proposed to prevent or treat this infection …